References
- Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, et al. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatol (United Kingdom). 2021. DOI:https://doi.org/10.1093/rheumatology/keaa587.
- Jorgensen SCJ, Tse CLY, Burry L, et al. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020. DOI:https://doi.org/10.1002/phar.2438
- Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, et al. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. Infection. 2021;1–14. DOI:https://doi.org/10.1007/s15010-021-01730-6
- NICE. Rapid policy statement interim clinical commissioning policy: neutralising monoclonal antibodies and intravenous antivirals in the treatment of COVID-19 in hospitalised patients commissioning position. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/09/C1529-interim-clinical-comm-policy-neutralising-monoclonal-antibodies-and-intravenous-antivirals.pdf (2021).
- Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
- Spinelli FR, Conti F, Gadina M. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Sci Immunol. 2020;5(47). DOI:https://doi.org/10.1126/sciimmunol.abc5367
- Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31.
- Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407–1418.
- Stebbing J, Sánchez Nievas G, Falcone M, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021;7(1). DOI:https://doi.org/10.1126/sciadv.abe4724
- Petrone L, Petruccioli E, Alonzi T, et al. In-vitro evaluation of the immunomodulatory effects of Baricitinib: implication for COVID-19 therapy. J Infect. 2021;82(4):58–66.
- Ziegler CGK, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016–1035.e19.
- Vaduganathan M, Vardeny O, Michel T, et al. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–1659.
- Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807.
- Horby PW, Emberson JR, Mafham M, et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analy-sis. medRxiv. [PREPRINT]. 2022. DOI:https://doi.org/10.1101/2022.03.02.22271623.
- Ely EW, Ramanan AV, de Bono S, et al. Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or Extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial. medRxiv. 2021;2021(10.11.21263897). DOI:https://doi.org/10.1101/2021.10.11.21263897
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826.
- RECOVERY collaborative group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021. DOI:https://doi.org/10.1056/nejmoa2021436.
- Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335–343.
- Peng L, Xiao K, Ottaviani S, et al. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;19(11):1505–1511.
- Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46(1):7–18.
- Kmietowicz Z. Covid-19: WHO recommends baricitinib and sotrovimab to treat patients. BMJ. 2022;376:376:o97.
- FDA. FDA emergency use authorisation for Baricitinib in the treatment of COVID-19.
- Buonsenso D, Riitano F, Valentini P. Pediatric inflammatory multisystem syndrome temporally related with SARS-CoV-2: immunological similarities with acute rheumatic fever and toxic shock syndrome. Front Pediatr. 2020;8. DOI:https://doi.org/10.3389/fped.2020.00574.
- Son MBF, Murray N, Friedman K, et al. Multisystem inflammatory Syndrome in children — initial therapy and outcomes. N Engl J Med. 2021;385(1):23–34.
- Fleming PF, Gale C, Molloy EJ, et al. Paediatric research in the times of COVID-19. Pediatr Res. 2021;90(2):267–271.